Pulse Biosciences (PLSE) Operating Expenses (2015 - 2025)

Pulse Biosciences' Operating Expenses history runs 11 years deep, the most recent figure standing at $20.5 million for Q3 2025.

• On a quarterly basis, Operating Expenses rose 49.78% year-over-year to $20.5 million in Q3 2025; TTM through Dec 2025 was $58.8 million, a 4.47% increase from a year earlier, with the FY2024 full-year figure at $56.3 million, up 29.11% from the prior year.
• Operating Expenses grew to $20.5 million in Q3 2025 per PLSE's latest filing, from $20.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.5 million in Q3 2025 and bottomed at $8.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $14.8 million (2021), against an average of $14.8 million.
• Across the five-year window, Operating Expenses sank 46.25% in 2022 and surged 72.91% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $16.3 million in 2021, then sank by 46.25% to $8.7 million in 2022, then jumped by 43.46% to $12.5 million in 2023, then surged by 61.66% to $20.3 million in 2024, then climbed by 0.95% to $20.5 million in 2025.
• Per Business Quant, the three latest PLSE Operating Expenses figures stand at $20.5 million (Q3 2025), $20.3 million (Q2 2025), and $18.0 million (Q1 2025).